Physician profile
Michael V Jablonski
NPI 1003815812
$17,158.51
in general payments reported to CMS, 2019-2025
11 companies · $5,253 in 2025
The $5,253 reported for 2025 was more than what 83% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $1,219 · 2021: $3,790 · 2022: $277 · 2023: $2,141 · 2024: $1,903 · 2025: $5,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,059 · Food and Beverage: $3,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,059.32 |
| Food and Beverage | $3,237.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $7,651.17 | 2019-2025 | Triathlon, Mako, Blueprint Patient Specific Instrumentation |
| Arthrex, INC. | $4,696.36 | 2019-2025 | |
| Reel Surgical, INC. | $3,991.31 | 2020-2025 | |
| Next Science LLC | $328.28 | 2024-2025 | Xperience, Blastx, Surgx |
| Miach Orthopaedics, INC. | $156.04 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $138.44 | 2020-2023 | Iovera |
| Anika Therapeutics, INC. | $80.78 | 2023 | X-Twist, Tactoset |
| Baudax Bio INC. | $56.09 | 2020 | |
| Innovation Technologies INC | $26.67 | 2025 | Irrisept |
| Orthopediatrics Corp. | $16.92 | 2025 | |
| Merck Sharp & Dohme LLC | $16.45 | 2023 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jablonski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.